A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Authors : Lalami Y, Garcia C, Flamen P, Ameye L, Paesmans M, Awada A
Year : 2016
Journal : Head Neck
Volume : 38(3)
Pages : 347-54